Literature DB >> 7030541

Neutrophil function in chronic liver disease.

A C Campbell, M W Dronfield, P J Toghill, W G Reeves.   

Abstract

Neutrophil locomotion, phagocytosis and killing of Candida albicans, and plasma opsonization of brewer's yeast were studied in 44 out-patients with chronic liver disease. There were four diagnostic groups: alcoholic liver disease (ALD), chronic active hepatitis (CAH), primary biliary cirrhosis (PBC) and cryptogenic cirrhosis (CC). Results were compared with a control group of patients with non-malignant disorders of the upper alimentary tract. Neutrophil locomotion induced by zymosan-activated autologous plasma was significantly depressed in patients with ALD and, to a lesser extent, in cryptogenic cirrhosis. With plasma from healthy donors, the patients' neutrophils showed normal locomotion. Plasma from patients with CAH gave slightly but significantly reduced phagocytosis of both Candida albicans and brewer's yeast, but the patients' cells had normal phagocytic and killing activity in the presence of normal plasma. Thus, no intrinsic abnormality in neutrophil function was found in these patients, but plasma defects, which differed in cirrhoses of different underlying aetiology, led to impaired neutrophil locomotion or phagocytosis. No correlations were found between these plasma defects and circulating levels of C3, C4, immune complexes or IgA.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7030541      PMCID: PMC1537247     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Comparative response of normal and cirrhotic rats to intravenously injected bacteria.

Authors:  A M RUTENBURG; E SONNENBLICK; I KOVEN; F SCHWEINBURG; J FINE
Journal:  Proc Soc Exp Biol Med       Date:  1959-06

2.  Total haemolytic complement after liver transplantation and in liver disease.

Authors:  A P Pagaltsos; M G Smith; A L Eddleston; R Williams
Journal:  Transplantation       Date:  1972-07       Impact factor: 4.939

3.  Significance of serum complement levels in chronic liver disease.

Authors:  N D Finlayson; K Krohn; M H Fauconnet; K E Anderson
Journal:  Gastroenterology       Date:  1972-10       Impact factor: 22.682

4.  Serum immunoglobulins, complement component levels and autoantibodies in liver disease.

Authors:  R A Thompson; R Carter; R P Stokes; A M Geddes; J A Goodall
Journal:  Clin Exp Immunol       Date:  1973-07       Impact factor: 4.330

5.  Spontaneous bacterial peritonitis in cirrhosis: variations on a theme.

Authors:  H O Conn; J M Fessel
Journal:  Medicine (Baltimore)       Date:  1971-05       Impact factor: 1.889

6.  Defective chemotaxis associated with a serum inhibitor in cirrhotic patients.

Authors:  A N DeMeo; B R Andersen
Journal:  N Engl J Med       Date:  1972-04-06       Impact factor: 91.245

Review 7.  Infections due to gram-negative organisms: an analysis of 860 patients with bacteremia at the University of Minnesota Medical Center, 1958-1966.

Authors:  H L DuPont; W W Spink
Journal:  Medicine (Baltimore)       Date:  1969-07       Impact factor: 1.889

8.  Bacterial endocarditis--a changing pattern.

Authors:  M M Uwaydah; A N Weinberg
Journal:  N Engl J Med       Date:  1965-12-02       Impact factor: 91.245

9.  Inhibition of leukocyte migration by a staphylococcal factor.

Authors:  B B Weksler; M J Hill
Journal:  J Bacteriol       Date:  1969-06       Impact factor: 3.490

10.  Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor.

Authors:  S H Zigmond; J G Hirsch
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

View more
  14 in total

Review 1.  Problems of bacterial infection in patients with liver disease.

Authors:  R J Wyke
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

Review 2.  Infectious complications of liver disease.

Authors:  P D King
Journal:  J Gen Intern Med       Date:  1993-06       Impact factor: 5.128

3.  Impaired opsonization by serum from patients with chronic liver disease.

Authors:  R J Wyke; I A Rajkovic; R Williams
Journal:  Clin Exp Immunol       Date:  1983-01       Impact factor: 4.330

4.  Neutrophil adherence in chronic liver disease and fulminant hepatic failure.

Authors:  M Altin; I A Rajkovic; R D Hughes; R Williams
Journal:  Gut       Date:  1983-08       Impact factor: 23.059

5.  Decreased production of active oxygen species by neutrophils in patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  K Itoh; A Nakao; W Kishimoto; T Itoh; A Harada; T Nonami; M Nakano; H Takagi
Journal:  Gastroenterol Jpn       Date:  1993-08

6.  Functions of granulocytes and monocytes in primary biliary and alcoholic cirrhosis.

Authors:  A Blussé van Oud; A R Janssens; P C Leijh; R van Furth
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

7.  Neutrophil phagocytic and bactericidal function in primary biliary cirrhosis and other chronic liver diseases.

Authors:  M A De Fernandez; A Clark; D R Triger
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330

8.  Serum inhibition of complement derived leukocyte chemotaxis and levels of immunoglobulin A subclass in alcoholic liver disease.

Authors:  S Onishi; T Saibara; T Maeda; Y Yamamoto; K Ito
Journal:  Gastroenterol Jpn       Date:  1989-06

9.  Dysfunctional neutrophil effector organelle mobilization and microbicidal protein release in alcohol-related cirrhosis.

Authors:  Thomas H Tranah; Godhev K Manakkat Vijay; Jennifer M Ryan; R Daniel Abeles; Paul K Middleton; Debbie L Shawcross
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-06-22       Impact factor: 4.052

10.  The Effect of Adrenal Replacement Therapy on Rates of Fungal Colonization and Mortality in Critically Ill Patients Awaiting Liver Transplantation.

Authors:  Stephanie G Yi; Archana R Sadhu; Stephen L Jones; Krista Turner; Howard Monsour; Kevin Donahue; Xuefeng Xia; A Osama Gaber; R Mark Ghobrial; Sherilyn Gordon Burroughs
Journal:  J Clin Transl Hepatol       Date:  2013-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.